Heterobicyclic compounds

A compound of Formula (I):

• or a pharmaceutically-acceptable salt, tautomer, or stereoisomer thereof, wherein:
• each p and q is independently 1;
• wherein the sum of p and q is 2;
• m is 0, 1, 2, 3, or 4;
• A is a 9- to 10-membered heterocyclic ring having the formula:
• wherein the group —W-T-D< is selected from the group consisting of:
• —N═CR5—N<;
• NR7—N═C<;
• —NR7—(C═O)—N<;
• NR7—CR6R7—(C═O)—N<;
• —NR7—(SO2)—N<;
• —CR5═CR5—N<;
• —CR8═N—N<;
• —CR6R7—(C═O)—N<;
• —CR6R7—NR7—(C═O)—N<;
• —CR6R7—O—(C═O)—N<;
• —CR6R7—(SO2)—N<;
• —O—(C═O)—N<;
• and —O—CR6R7—(C═O)—N<;
• J is CR3c;
• wherein each E, X, Y, and Z is independently N or CR4;
• wherein 1, 2, or 3 of E, X, Y, and Z are N;
• G is R1, —NR1R2;
• —NH(C═O)R1;
• —OR 1, —(C═O)R1;
• or —CHR1R2;
• R1 is a carbon-linked or nitrogen-linked saturated, partially-saturated or unsaturated 9- or 10-membered bicyclic ring, wherein each said ring contains 0, 1, 2, 3, or 4 N atoms and 0, 1, or 2 O or S atoms;
• wherein each R1 is independently substituted by 0, 1, 2 or 3 R9 groups;
• R2 is independently H, OH, C1-4alk, a carbon-linked or nitrogen-linked saturated, partially-saturated, or unsaturated 5- or 6-membered monocyclic ring, wherein each said ring contains 0, 1, 2, 3, or 4 N atoms and 0, 1, or 2 O or S atoms;
• wherein each R2 C1-4alk or monocyclic ring is independently substituted by 0, 1, 2 or 3 R9 groups;
• each R3a and R3c is independently H, F, OH, C1-4alk, or C1-4haloalk;
• R3b is independently F, Cl, Br, CN, OH, OC1-4alk, C1-4alk, C1-4haloalk, or oxo;
• R4 is halo, R4a, —SR4a, —OR4a, —NHR4a, or —N(C1-4alk)R4a, wherein —R4a is H, C1-4alk, a saturated, partially-saturated or unsaturated 3-, 4-, 5- or 6-membered monocyclic ring, wherein each said ring contains 0, 1, 2, 3, or 4 N atoms and 0, 1, or 2 O or S atoms;
• wherein each R4 C1-4alk or monocyclic ring is independently substituted by 0, 1, 2 or 3 R9 groups;
• each R5 is independently R5a, —OR5b, —NHR5a, or —N(C1-4alk)R5a, wherein R5a is H or C1-4alk;
• R5b is C1-4alk, a saturated, partially-saturated or unsaturated 3-, 4-, 5- or 6-membered monocyclic ring, wherein each said ring contains 0, 1, 2, 3, or 4 N atoms and 0, 1, or 2 O or S atoms;
• wherein each R5 C1-4alk or monocyclic ring is independently substituted by 0, 1, 2 or 3 R9 groups;
• each R6 and R7 is independently H, halo, OH, C1-4alk, OC1-4alk, a saturated, partially-saturated or unsaturated 3-, 4-, 5- or 6-membered monocyclic ring, wherein each said ring contains 0, 1, 2, 3, or 4 N atoms and 0, 1, or 2 O or S atoms;
• wherein each R6 and R7 C1-4alk or monocyclic ring is independently substituted by 0, 1, 2 or 3 R9 groups;
• or R6 and R7 may optionally form a saturated or partially-saturated 3-, 4-, 5- or 6-membered monocyclic ring, wherein each said ring contains 0, 1, 2, 3, or 4 N atoms and 0, 1, or 2 O or S atoms;
• wherein said monocyclic ring is independently substituted by 0, 1, 2 or 3 R9 groups;
• R8 is R8a, —O—R8a, —NHR8a, or —N(C1-4alk)R8a, wherein R8a is H, C1-4alk, a saturated, partially-saturated or unsaturated 3-, 4-, 5- or 6-membered monocyclic ring, wherein each said ring contains 0, 1, 2, 3, or 4 N atoms and 0, 1, or 2 O or S atoms;
• wherein each R8 C1-4alk or monocyclic ring is independently substituted by 0, 1, 2 or 3 R9 groups;
• R9 is independently F, Cl, Br, C1-6alk, C1-4haloalk, —ORa, ORc, —OC1-4haloalk, CN, —C(═O)Rb, —C(═O)Rc, —C(═O)ORa, —C(═O)NRaRa, —C(═O)NRaRc, —C(═NRa)NRaRa, —OC(═O)Rb, —OC(═O)NRaRa, —OC1-6alkNRaRa, —OC1-6alkORa, —SRa, —S(═O)Rb, —S(═O)2Rb, —S(═O)2NRaRa, —NRaRa, —N(Ra)C(═O)Rb, —N(Ra)C(═O)ORb, —N(Ra)C(═O)NRaRa, —N(Ra)C(═NRa)NRaRa, —N(Ra)S(═O)2Rb, —N(Ra)S(═O)2NRaRa, —NRaC1-6alkNRaRa, —NRaC1-6alkORa, —C1-6alkNRaRa, —C1-6alkORa, —C1-6 alkN(Ra)C(═O)Rb, —C1-6alkOC(═O)Rb, —C1-6alkC(═O)NRaRa, —C1-6alkC(═O)ORa, or oxo;
• R10 is halo, C1-6alk, C1-4haloalk, —ORa, —OC1-4haloalk, CN, —C(═O)Rb, —C(═O)ORa, —C(═O)NRaRa, —C(═NRa)NRaRa, —OC(═O)Rb, —OC(═O)NRa Ra, —OC1-6alkNRaRa, —OC1-6alkORa, —SRa, —S(═O)Rb, —S(═O)2Rb, —S(═O)2NRaRa, —NRaRa, —N(Ra)C(═O)Rb, —N(Ra)C(═O)ORb, —N(Ra)C(═O)NRaRa, —N(Ra)C(═NRa)NRaRa, —N(Ra)S(═O)2Rb, —N(Ra)S(═O)2NRaRa, —NRaC1-6alkNRaRa, —NRaC1-6alkORa, —C1-6alkNRaRa, —C1-6alkORa, —C1-6alkN(Ra)C(═O)Rb, —C1-6alkOC(═O)Rb, —C1-6alkC(═O))NRaRa, —C1-6alkC(═O)ORa, or oxo;
• Ra is independently H or Rb;
• Rb is independently phenyl, benzyl, or C1-6alk, wherein said phenyl, benzyl, and C1-6alk are substituted by 0, 1, 2 or 3 substituents which are C1-4alk, C1-3haloalk, —OH, —OC1-4alk, —NH2, —NHC1-4alk, —OC(═O)C1-4alk, or —N(C1-4alk)C1-4alk;
• and
• Rc is independently a carbon-linked or nitrogen-linked saturated, partially-saturated or unsaturated 3-, 4-, 5-, 6-, or 7-membered monocyclic ring or a saturated, partially-saturated or unsaturated 6-, 7-, 8-, 9-, 10-, 11-, or 12-membered bicyclic ring, said ring contains 0, 1, 2, 3, or 4 N atoms and 0, 1, or 2 atoms which are O or S;
• Rc is independently substituted by 0, 1, 2 or 3 R10 groups.